News Conference News HFSA 2025 Too Few HF Patients on Guideline-Directed Medical Therapy in VA System Yael L. Maxwell October 06, 2025
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Conference News HFSA 2023 STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization L.A. McKeown October 18, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Daily News HFSA 2021 In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity Michael O'Riordan September 15, 2021
News Conference News HFSA 2021 Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF Michael O'Riordan September 14, 2021
News Conference News HFSA 2020 More HF Readmissions Among Black People From Deprived Neighborhoods L.A. McKeown October 06, 2020
News Conference News HFSA 2019 Old Dog, New Tricks? HOMAGE Hints at Role for Spironolactone in HF Prevention L.A. McKeown September 24, 2019